01AI / BIO
The filing says Claude is used in drug discovery and development, in a sector where annual global pharmaceutical spend is expected to exceed $2 trillion in 2026. The same week, Anthropic said it had acquired Mithril Medicine, a one-person company whose founder used Claude to run contracts, logistics and experiments across 11 external labs. Mithril took a possible muscular dystrophy treatment to promising mouse results in under 18 months; if its candidates hold up, Anthropic expects human trials as soon as late 2028.
Anthropic ↗02CAPITAL
Formation Bio, an AI-native pharmaceutical company, plans to acquire 10 to 15 drug programs over the next 3 to 5 years and take them through key clinical milestones. Its limited partners include research foundations, endowments, hospitals and philanthropic organizations, and Formation Bio has committed its own capital. Each program sits in its own corporate entity.
Formation Bio (PR Newswire) ↗03CAPITAL
BioGeometry builds what it calls world models: GeoFlow for molecules and GeoCell for cells. It says GeoFlow V3, which refines designs through in silico evolution, reached an average hit rate of nearly 20% across more than 20 targets and cut lead discovery to under three weeks. Several of its bispecific antibody programs are expected to reach the IND stage in 2027.
BioGeometry ↗
